|
MedImmune to create stand-alone company for early-stage inflammation and autoimmunity biologics
|
28 February 2018 |
|
Brilinta significantly reduces CV events and coronary death beyond one year in heart attack survivors with multi-vessel disease
|
07 February 2018 |
|
AstraZeneca listed as one of the world's top-100 most sustainable companies and recognised for its three-fold increase in renewable energy usage
|
23 January 2018 |
|
New research paper shows that AstraZeneca has achieved greater than four-fold improvement in R&D productivity
|
19 January 2018 |
|
US FDA accepts regulatory submission for Tagrisso in 1st-line EGFR-mutated non-small cell lung cancer
|
18 December 2017 |
|
AstraZeneca and Chinese Future Industry Investment Fund establish joint venture to develop new medicines in China
|
27 November 2017 |
|
Fasenra (benralizumab) receives US FDA approval for severe eosinophilic asthma
|
15 November 2017 |
|
FDA approves AstraZeneca's Calquence (acalabrutinib) for adult patients with previously-treated mantle cell lymphoma
|
31 October 2017 |
|
FDA accepts regulatory submission for Lynparza in metastatic breast cancer and grants Priority Review
|
18 October 2017 |
|
Tagrisso granted breakthrough therapy designation by US FDA for the 1st-line treatment of patients with EGFR mutation-positive non-small cell lung cancer
|
11 October 2017 |